Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01707368|
Recruitment Status : Completed
First Posted : October 16, 2012
Results First Posted : September 24, 2018
Last Update Posted : September 24, 2018
|Condition or disease||Intervention/treatment|
|Psoriasis Vulgaris Plaque Psoriasis||Drug: Daivobet® Gel|
|Study Type :||Observational|
|Actual Enrollment :||561 participants|
|Official Title:||Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||July 2014|
all eligible patients
Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Drug: Daivobet® Gel
Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
- The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient`s Individual Application Habits Under Daily Use Conditions. [ Time Frame: 1 year ]Number of exacerbations and relapses during one year observation time
- PGA (Physician's Global Assessment of Psoriasis Vulgaris Severity) [ Time Frame: Baseline ]6--point verbal rating scale
- PGA (Physician's Global Assessment of Psoriasis Vulgaris Severity) [ Time Frame: 1 year ]Assessment on 6-step scale from "no visible disease (O)" to "very severe disease (5)
- Side Effects [ Time Frame: 1 year ]Number of participants with serious and non-serious adverse drug reactions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707368
|PD Dr. med. Rosenbach|
|Osnabrück, Niedersachsen, Germany, 49078|
|Principal Investigator:||Thomas Rosenberg, PD Dr. med.||private practise, D- 49078 Osnabrück, Germany|